PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.30%
Negative revenue growth while ADI stands at 14.98%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.22%
Negative gross profit growth while ADI is at 17.93%. Joel Greenblatt would examine cost competitiveness or demand decline.
15.97%
EBIT growth 50-75% of ADI's 22.04%. Martin Whitman would suspect suboptimal resource allocation.
15.09%
Operating income growth at 50-75% of ADI's 22.04%. Martin Whitman would doubt the firm’s ability to compete efficiently.
-6.77%
Negative net income growth while ADI stands at 3.99%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2.56%
Negative EPS growth while ADI is at 3.70%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.63%
Negative diluted EPS growth while ADI is at 4.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.73%
Share count expansion well above ADI's 0.58%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.08%
Slight or no buyback while ADI is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
4.95%
Dividend growth of 4.95% while ADI is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
34.22%
OCF growth under 50% of ADI's 129.76%. Michael Burry might suspect questionable revenue recognition or rising costs.
-197.20%
Negative FCF growth while ADI is at 285.65%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
29.76%
10Y revenue/share CAGR under 50% of ADI's 356.22%. Michael Burry would suspect a lasting competitive disadvantage.
-26.65%
Negative 5Y CAGR while ADI stands at 335.70%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
12.01%
3Y revenue/share CAGR under 50% of ADI's 118.53%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-2.10%
Negative 10Y OCF/share CAGR while ADI stands at 1202.11%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
7.60%
Below 50% of ADI's 315.51%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
24.27%
3Y OCF/share CAGR under 50% of ADI's 117.94%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
953.20%
Net income/share CAGR 1.25-1.5x ADI's 764.25%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
90.10%
Below 50% of ADI's 689.53%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
299.75%
3Y net income/share CAGR 1.25-1.5x ADI's 254.16%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
302.95%
10Y equity/share CAGR at 50-75% of ADI's 427.22%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
168.64%
Below 50% of ADI's 388.28%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
91.42%
3Y equity/share CAGR similar to ADI's 90.95%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
21.42%
Dividend/share CAGR of 21.42% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-2.02%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-2.13%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-6.69%
Firm’s AR is declining while ADI shows 10.34%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
9.89%
Inventory growth well above ADI's 5.80%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-3.38%
Negative asset growth while ADI invests at 49.47%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.45%
Under 50% of ADI's 11.25%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-3.74%
We’re deleveraging while ADI stands at 3753.50%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-17.26%
Our R&D shrinks while ADI invests at 19.33%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-11.48%
We cut SG&A while ADI invests at 4.37%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.